# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Laidlaw & Co. analyst Yale Jen downgrades MEI Pharma (NASDAQ:MEIP) from Buy to Hold.
Company Commences a Cash Preservation Plan Including a Reduction in ForceMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company")...
MEI Pharma (NASDAQ:MEIP) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.52) by...
Stifel analyst Stephen Willey maintains MEI Pharma (NASDAQ:MEIP) with a Hold and maintains $7 price target.
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023...
– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study –– ME-344 in Combination with Bevacizu...